WEKO3
-
RootNode
アイテム
Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib
http://hdl.handle.net/10295/00006175
http://hdl.handle.net/10295/00006175e771d198-33e2-4bf4-8498-2bdc64c5a4ce
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
iA_2022_40.pdf (1.1 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-02-19 | |||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||
| タイトル | Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib | |||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||||
| 主題 | metastatic renal cell carcinoma | |||||||||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||||
| 主題 | molecular-targeted therapy | |||||||||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||||
| 主題 | plasminogen activator inhibitor-1 | |||||||||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||||
| 主題 | serum biomarker | |||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||||||||||||||
| 作成者 |
Honma, Naoko
× Honma, Naoko
× Inoue, Takamitsu
× Tsuchiya, Norihiko
× Koizumi, Atsushi
× Yamamoto, Ryohei
× Nara, Taketoshi
× Kanda, Sohei
× Huang, Mingguo
× Numakura, Kazuyuki
× Saito, Mitsuru
× Narita, Shintaro
× Satoh, Shigeru
× Habuchi, Tomonori
|
|||||||||||||||||||||||||||||||
| 内容記述 | ||||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||||
| 内容記述 | Background and AimsVascular endothelial growth factor-directed therapies play a significant role in patients with metastatic renal cell carcinoma (mRCC). Biomarkers for predicting treatment efficacy and resistance are required to develop personalized medicine. We evaluated multiple serum cytokine levels in patients with mRCC treated with axitinib to explore predictive biomarkers. MethodsFrom September 2012 to October 2015, serum samples were collected from 44 patients with mRCC before treatment and 4weeks after axitinib initiation. Bio-Plex Pro Human Cancer Biomarker Panels 1 and 2 were used to measure levels of 34 serum biomarkers related to angiogenesis and cell proliferation. ResultsPatients with partial response or stable disease had significantly decreased serum plasminogen activator inhibitor-1 (PAI-1) level from pre-treatment to 4weeks after axitinib initiation compared with those with progressive disease (P = .022). The median progression-free survival (PFS) and median overall survival (OS) in patients with increased serum PAI-1 level from pre-treatment to 4weeks after axitinib initiation were significantly shorter than those with decreased serum PAI-1 level (P = .027 and P = .026, respectively). Increased serum PAI-1 level from pre-treatment to 4weeks after axitinib initiation was an independent prognostic marker for shorter PFS and OS in multivariate analyses (P = .015 and P = .032, respectively). The immunohistochemical staining intensity of PAI-1 in tumor specimens was significantly associated with Fuhrman grade and presence of distant metastasis (P = .026 and P = .010, respectively). ConclusionsThe initial change in serum PAI-1 level in the early stage of axitinib treatment could be a useful prognostic biomarker in patients with mRCC. | |||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||||
| 書誌情報 |
en : Health Science Reports 巻 3, 号 4, 発行日 2020 |
|||||||||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||||
| 収録物識別子 | 2398-8835 | |||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||
| 出版者 | John Wiley and Sons Inc | |||||||||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1002/hsr2.197 | |||||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||||
| 権利情報 | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2020 The Authors. Health Science Reports published by Wiley Periodicals LLC. | |||||||||||||||||||||||||||||||
